Fixed ‐dose combination of sofosbuvir and ledipasvir in the treatment of hepatitis C infection in patients on hemodialysis: Report of an initial experience
Although our Dialysis Outcomes and Practice Patterns Study reported a relatively slow international decrease of hepatitis C virus (HCV) prevalence and incidence in hemodialysis (HD) units from 1996 to 20121 (before the direct-acting antiviral era), Huang et al. now report their direct-acting antiviral–based elimination of HCV from a single HD unit in Taiwan.2 Such eradication of HCV will reduce the clinical burden associated with HCV infection. In addition, HCV eradication should prevent HCV nosocomial transmission.
We read the report by Jadoul et al.1 with great interest in a recent issue in Kidney International. The World Health Organization has set ambitious goals for hepatitis C virus (HCV) eradication using the “micro-elimination” approach.2 Taiwan has one of the highest prevalence and incidence of end-stage kidney disease worldwid e. HCV infection is an important complication among our hemodialysis patients.3 With the advent of the new direct-acting antivirals, complete eradication of HCV infection is one of our key priorities.
ConclusionIn a real-life scenario, HCV seroconversion is observed in 15% of the patients initiated on hemodialysis. Isolation of both dialysis machine and personnel was associated with lower seroconversion.
Conclusions: Phylogenetic analyses confirmed nosocomial transmission during dialysis as a major factor in the spread of HCV at the seven dialysis centers in Kosovo.
Authors: Fayed A, Soliman A, El Mahdy H, Hamza W, Abdulazim DO, Salem MM, Sharaf El Din UA, Vascular Calcification Group (VCG) Abstract BACKGROUND: The impact of hepatitis virus infection on arterial calcification (AC) was not studied. OBJECTIVE: To study the prevalence, severity and distribution of AC in incident hemodialysis patients with hepatitis B and C viral infection. CASES AND METHODS: 172 stage 5 CKD adults (98 male and 74 female) were included; 58 of them were seronegative for both hepatitis B and C (SN group), 48 were positive for hepatitis B virus infection (HBV group) and 66 were hepatitis C vi...
ConclusionOur study showed excellent efficacy with the safety profile of this drug combination in end-stage renal disease patients. However, larger prospective studies and multicenter randomized controlled trials are needed for further confirmation.
There is paucity of data using direct anti-viral agents (DAA) in patients on maintenance hemodialysis (MHD) infected with HCV-genotype 1&3. Aim of the study was to evaluate DAA therapy in patients infected w...
Conclusion: Prevalence of transfusion-transmissible viral infections was higher among hemodialysis patients, especially HCV infection which was an alarming situation and therefore strict adherence to infection control strategies, barrier precautions, and preventive measures, including routine hepatitis B vaccination and regular virological follow-up were recommended along with regular education and training programs of technical and nursing personnel's involved with dialysis patients.
ConclusionSofosbuvir-based regimens are effective to treat HCV in patients with CKD. In patients with mild CKD this type of therapy seems to be safe.